Fertility-sparing treatment using medroxyprogesterone acetate for endometrial carcinoma
Fertility-sparing treatment using medroxyprogesterone acetate for endometrial carcinoma
复制标题
DOI：
10.3892/ol.2012.602
复制
发表时间：
2012-05-01
期刊：
影响因子：
2.9
通讯作者：
Suzuki, Mitsuaki
中科院分区：
文献类型：
--
作者：
Fujiwara, Hiroyuki;Jobo, Toshiko;Suzuki, Mitsuaki
本研究的目的是介绍醋酸羟孕酮（MPA）保留生育能力治疗子宫内膜癌（EC）的结果，并通过调查患者背景因素来阐明患者的特征。在1987年至2008年的21年间，共有59例EC患者在两个机构接受了MPA作为保留生育能力的治疗，回顾性研究。只要患者有反应，就给予口服MPA 400- 600mg /天，持续16-24周。子宫内膜组织评估两次，在8-12周（治疗期间）和治疗后不久。总完全缓解（CR）率为71%。42名应答者中有22名（52%）后来复发。共有19例患者怀孕，25名婴儿出生。80%的复发发生在2年内。对于la期和Ib-IIa期（FIGO, 1988），初始CR率分别为80.0和42.9%
The purpose of this study was to present the results of fertility-sparing treatment using medroxyprogesterone acetate (MPA) for endometrial carcinoma (EC), and to clarify patient characteristics by investigating patient background factors. A total of 59 patients with EC, who received MPA as fertility-sparing therapy at two institutions over a 21-year period between 1987 and 2008, were studied retrospectively. Patients were administered oral MPA at 400-600 mg/day for 16-24 weeks as long as they responded. Endometrial tissue was assessed twice, at 8-12 weeks (during treatment) and shortly after treatment. The overall complete response (CR) rate was 71%. A total of 22 (52%) of 42 responders later developed relapse. A total of 19 cases became pregnant, and 25 infants were born. Eighty percent of recurrences occurred within 2 years. For stages la and Ib-IIa (FIGO, 1988), initial CR rates were 80.0 and 42.9%, respectively (p